Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 65   

Articles published

JNJ 100.50 -3.42 (-3.29%)
price chart
Johnson & Johnson facing massive class action
Medical giant Johnson & Johnson is facing its third class action in Australia in as many years, with a case filed in the Federal Court yesterday which relates to a product called transvaginal mesh.
Johnson & Johnson Agrees to Settle Five Rispersal Suits
Johnson & Johnson agreed to settle five lawsuits over claims that its antipsychotic drug Risperdal caused increased breast-tissue growth in boys.
Johnson & Johnson diabetes drug effective in high risk patients
An experimental treatment for type 2 diabetes developed by Johnson & Johnson proved effective at reducing blood sugar in patients on long-term insulin therapy and at high risk for heart problems, according to a study presented on Tuesday.
Done with Creative Review, J&J Turns Sights to Global Media Review
Johnson & Johnson has concluded its global creative agency review and is preparing to launch a global media review in markets not already in review, including North America, company executives said today.
Johnson & Johnson, Mayor Booker Partner for Better Health
When I say the words Johnson & Johnson, you can probably smell the baby shampoo we all used as children and which you may still use with your own children.
J&J's Global Creative Review Nears Finish
Johnson & Johnson is close to concluding its global review of creative responsibilities for its over-the-counter brands and sources expect the bulk of the business to be consolidated at three roster shops: DDB, BBDO and JWT.
J&J Set to Consolidate Creative With Omnicom, WPP  AdAge.com
J.&J.'s Costs Take a Toll on Its Profit
Revenue rose 6.5 percent to $17.05 billion, pushed up nearly 6 percent by sales from Synthes Inc., a maker of surgical trauma equipment and orthopedic implants.
Johnson & Johnson Tops Forecasts on Lower Profit  Investorplace.com
J&J reaps benefit of Synthes acquisition  Financial Times
Five reasons to like Johnson & Johnson
Johnson & Johnson has made headlines over the past couple of years - for all the wrong reasons. Plagued by quality control problems and costly product recalls affecting key brands such as Tylenol, Benadryl and Motrin, the health care giant's reputation ...
Tylenol and the Legacy of J&J's James Burke
This post is in partnership with Knowledge@Wharton, the online research and business analysis journal of the Wharton School of the University of Pennsylvania.
Strong earnings reports from Mattel, Goldman Sachs, Johnson & Johnson help ...
Unexpectedly strong earnings reports from heavyweights like Mattel and Johnson & Johnson streamed in on Tuesday, helping fuel a rally on Wall Street.